title: Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation.
authors.forename: T
authors.initials: T
authors.lastname: Lange
authors.forename: T
authors.initials: T
authors.lastname: Bumm
authors.forename: M
authors.initials: M
authors.lastname: Mueller
authors.forename: S
authors.initials: S
authors.lastname: Otto
authors.forename: H-K
authors.initials: HK
authors.lastname: Al-Ali
authors.forename: L
authors.initials: L
authors.lastname: Grommisch
authors.forename: S
authors.initials: S
authors.lastname: Musiol
authors.forename: C
authors.initials: C
authors.lastname: Franke
authors.forename: R
authors.initials: R
authors.lastname: Krahl
authors.forename: D
authors.initials: D
authors.lastname: Niederwieser
authors.forename: M W N
authors.initials: MW
authors.lastname: Deininger
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D015331:Cohort Studies; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate